Sugi Predict

Sugi Predict / Compounds / SCHEMBL29968519

SCHEMBL29968519

SCHEMBL29968519

CC(C)(C)OC(=O)N1C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@]1(CN)CCc1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ OPRD1 P41143 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ STS P08842 1/20 0.33
▸ NR1H2 P55055 2/20 0.33
▸ NR1H3 Q13133 2/20 0.33
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ RORC P51449 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22776331 0.92 GAA (0.36) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL22776330 0.92 GAA (0.36) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL22776171 0.84 STS (0.34) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL22776178 0.83 GAA (0.34) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL22776177 0.83 GAA (0.34) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL15114603 0.76 ABCB1 (0.37) MEN1KMT2AGPR119ABCB1
SCHEMBL4980776 0.76 NR1H2 (0.41) NR1H2NR1H3RORCKDM1AGPR119
SCHEMBL4564095 0.76 JAK2 (0.39) GAATHRBSMN1; SMN2OPRD1OPRK1
SCHEMBL22776886 0.74 RORC (0.37) RORCKMT2AGPR119ABCB1
SCHEMBL22776888 0.74 RORC (0.37) RORCKMT2AGPR119ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983414-B1 HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2026-04-01 — — EP disclosed
US-12427159-B2 Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels MERCK SHARP & DOHME LLC (US) 2025-09-30 — — US disclosed
US-20220305035-A1 HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME CORP. (US) 2022-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427159-B2 Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels TRPV1, SCN1A, SCN7A GAA 3905/4885THRB 1920/4885SMN1; SMN2 282/4885
US-20220305035-A1 HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS TRPV1, SCN1A, SCN7A GAA 3905/4885THRB 1920/4885SMN1; SMN2 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.